Add to ORKGBecause a dose-response relationship is characteristic of conventional chemotherapy, this concept is widely used for the development of novel cytotoxic (CTX) drugs. However, the need to reach the MTD to obtain optimal benefit with molecularly targeted agents (MTA) is controversial. In this study, we evaluated the relationship between dose and efficacy in a large cohort of phase I patients with solid tumors.status: publishe
The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma. Experi...
Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safet...
The advancement of therapeutic strategies in oncology such as precision oncology has generated signi...
INTRODUCTION: Because a dose-response relationship is characteristic of conventional chemotherapy, t...
Introduction: Because a dose-response relationship is characteristic of conventional chemotherapy, t...
Introduction: Because a dose–response relationship is characteristic of conventional chemotherapy, t...
PURPOSE: Phase 1 trials play a crucial role in oncology by translating laboratory science into effic...
Phase 1 trials play a crucial role in oncology by translating laboratory science into efficient ther...
Knowledge of the relationships among dose, drug concentration in blood, and clinical response is imp...
such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose se...
Phase I clinical trials, the first studies in humans of a new anticancer agent or a new anticancer t...
Full list of author information is available at the end of the articlesystemic cancer therapy for ha...
Cancer is a global health problem. While there have been some major advances in the treatment of sol...
textabstractMost anticancer agents developed over the last four decades are cytotoxic drugs inducin...
Conventional dose-finding methods in oncology are mainly developed for cytotoxic agents with the aim...
The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma. Experi...
Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safet...
The advancement of therapeutic strategies in oncology such as precision oncology has generated signi...
INTRODUCTION: Because a dose-response relationship is characteristic of conventional chemotherapy, t...
Introduction: Because a dose-response relationship is characteristic of conventional chemotherapy, t...
Introduction: Because a dose–response relationship is characteristic of conventional chemotherapy, t...
PURPOSE: Phase 1 trials play a crucial role in oncology by translating laboratory science into effic...
Phase 1 trials play a crucial role in oncology by translating laboratory science into efficient ther...
Knowledge of the relationships among dose, drug concentration in blood, and clinical response is imp...
such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose se...
Phase I clinical trials, the first studies in humans of a new anticancer agent or a new anticancer t...
Full list of author information is available at the end of the articlesystemic cancer therapy for ha...
Cancer is a global health problem. While there have been some major advances in the treatment of sol...
textabstractMost anticancer agents developed over the last four decades are cytotoxic drugs inducin...
Conventional dose-finding methods in oncology are mainly developed for cytotoxic agents with the aim...
The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma. Experi...
Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safet...
The advancement of therapeutic strategies in oncology such as precision oncology has generated signi...